Medical Clinic II (Cardiology, Angiology, Intensive Care Medicine), University Heart Center Lübeck, Lübeck, Germany.
Curr Opin Crit Care. 2019 Aug;25(4):403-409. doi: 10.1097/MCC.0000000000000628.
Cardiogenic shock remains beside sudden cardiac death the most outcome relevant complication of acute myocardial infarction. Over the last two decades as confirmation of the benefit of early revascularization no further relevant improvement in outcome could be achieved. Biomarkers are important for diagnosis, monitoring, and management in cardiogenic shock patients.
A bunch of different biomarkers have been associated with prognosis in patients with cardiogenic shock. In routine use standard parameters such as serum lactate or serum creatinine are still most important in monitoring these patients. These established markers outperformed novel markers in prognostic impact in recent trials.
Biomarkers serve as important treatment targets and may help physicians in therapeutic decision-making. Furthermore, the complex pathophysiology of cardiogenic shock may be better understood by investigation of different biomarkers.
心原性休克除了心脏性猝死，仍是急性心肌梗死最相关的预后并发症。在过去二十年中，由于早期血运重建的益处已得到证实，因此在结果方面无法取得进一步的相关改善。生物标志物对于心原性休克患者的诊断、监测和管理非常重要。
许多不同的生物标志物与心原性休克患者的预后相关。在常规使用中，血清乳酸或血清肌酐等标准参数在监测这些患者时仍然是最重要的。在最近的试验中，这些已建立的标志物在预后影响方面优于新型标志物。
生物标志物可作为重要的治疗靶点，并有助于医生做出治疗决策。此外，通过研究不同的生物标志物，可以更好地了解心原性休克的复杂病理生理学。
